Seminars in Radiation Oncology
Volume 17, Issue 2 , Pages 108-120 , April 2007

Physical Models and Simpler Dosimetric Descriptors of Radiation Late Toxicity

References 

  1. Kong FM, Hayman JA, Griffith KA, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys. 2006;65:1075–1086
  2. Ben-Josef E, Lawrence TS. Radiotherapy for unresectable hepatic malignancies. Semin Radiat Oncol. 2005;15:273–278
  3. Lawrence TS. The role of radiation in liver cancer. Clin Adv Hematol Oncol. 2006;4:113–115
  4. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: Long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:324–333
  5. Ten Haken RK, Lawrence TS. The clinical application of intensity modulated radiation therapy. Semin Radiat Oncol. 2006;16:224–231
  6. Kong FM, Ten Haken R, Eisbruch A, et al. Non-small cell lung cancer therapy-related pulmonary toxicity: An update on radiation pneumonitis and fibrosis. Semin Oncol. 2005;32:S42–S54
  7. Ten Haken RK, Kessler ML. 3-D CRT Plan Evaluation. In:  Purdy JA,  Grant WH,  Palta JR,  Butler EB,  Perez CA editor. 3-D Conformal and Intensity Modulated Radiation Therapy. 16:Madison WI: Advanced Medical Publishing; 2001;p. 224–231
  8. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl. 1985;8:S13–S19
  9. Kallman P, Agren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol. 1992;62:249–262
  10. Burman C, Kutcher GJ, Emami B, et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys. 1991;21:123–135
  11. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–821
  12. Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis (Normal tissue complication probability). Int J Radiat Oncol Biol Phys. 2003;55:724–735
  13. Kutcher GJ, Burman C, Brewster L, et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys. 1991;21:137–146
  14. Schultheiss TE, Orton CG, Peck RA. Models in radiotherapy: volume effects. Med Phys. 1983;10:410–415
  15. Niemierko A, Goitein M. Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture. Radiother Oncol. 1991;20:166–176
  16. Jackson A, Kutcher GJ, Yorke ED. Probability of radiation-induced complications for normal tissues with parallel architecture subject to non-uniform irradiation. Med Phys. 1993;20:613–625
  17. Yorke ED, Kutcher GJ, Jackson A, et al. Probability of radiation-induced complications in normal tissues with parallel architecture under conditions of uniform whole or partial organ irradiation. Radiother Oncol. 1993;26:226–237
  18. Niemierko A, Goitein M. Modeling of normal tissue response to radiation: The critical volume model. Int J Radiat Oncol Biol Phys. 1993;25:135–145
  19. Thames HD, Zhang M, Tucker SL, et al. Cluster models of dose-volume effects. Int J Radiat Oncol Biol Phys. 2004;59:1491–1504
  20. Yorke ED. Modeling the effects of inhomogeneous dose distributions in normal tissues. Semin Radiat Oncol. 2001;11:197–209
  21. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122
  22. Ten Haken RK. Partial organ irradiation; Introduction. Semin Radiat Oncol. 2001;11:181–183
  23. Schultheiss TE. The controversies and pitfalls in modeling normal tissue radiation injury/damage. Semin Radiat Oncol. 2001;11:210–214
  24. Deasy JO, Niemierko A, Herbert D, et al. Methodological issues in radiation dose-volume outcome analyses: Summary of a joint AAPM/NIH workshop. Med Phys. 2002;29:2109–2127
  25. Denis F, Garaud P, Bardet E, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: Comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys. 2003;55:93–98
  26. Eisbruch A, Ten Haken RK, Kim HM, et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;45:577–587
  27. Blanco AI, Chao KS, El Naqa I, et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:1055–1069
  28. Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:695–704
  29. Cassatt DR, Fazenbaker CA, Bachy CM, et al. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. Semin Radiat Oncol. 2002;12:97–102
  30. Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: Initial results. Int J Radiat Oncol Biol Phys. 2001;49:907–916
  31. Jellema AP, Doornaert P, Slotman BJ, et al. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?. Radiother Oncol. 2005;77:164–171
  32. Roesink JM, Schipper M, Busschers W, et al. A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: Implications for future trials. Int J Radiat Oncol Biol Phys. 2005;63:1006–1009
  33. Braam PM, Roesink JM, Moerland MA, et al. Long-term parotid gland function after radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:659–664
  34. Eisbruch A, Rhodus N, Rosenthal D, et al. How should we measure and report radiotherapy-induced xerostomia?. Semin Radiat Oncol. 2003;13:226–234
  35. Trott KR, Herrmann T, Kasper M. Target cells in radiation pneumopathy. Int J Radiat Oncol Biol Phys. 2004;58:463–469
  36. Eisbruch A. Reducing radiation-induced xerostomia with highly conformal radiotherapy techniques. J Support Oncol. 2005;3:201–202
  37. Willner J, Jost A, Baier K, et al. A little to a lot or a lot to a little? (An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy). Strahlenther Onkol. 2003;179:548–556
  38. Rodrigues G, Lock M, D’Souza D, et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer—A systematic review. Radiother Oncol. 2004;71:127–138
  39. Rancati T, Ceresoli GL, Gagliardi G, et al. Factors predicting radiation pneumonitis in lung cancer patients: A retrospective study. Radiother Oncol. 2003;67:275–283
  40. Seppenwoolde Y, Lebesque JV. Partial irradiation of the lung. Semin Radiat Oncol. 2001;11:247–258
  41. Marks LB, Munley MT, Bentel GC, et al. Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys. 1997;39:563–570
  42. Armstrong J, Raben A, Zelefsky M, et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 1997;44:17–22
  43. Martel MK, Ten Haken RK, Hazuka MB, et al. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys. 1994;28:575–581
  44. Gagliardi G, Bjohle J, Lax I, et al. Radiation pneumonitis after breast cancer irradiation: Analysis of the complication probability using the relative seriality model. Int J Radiat Oncol Biol Phys. 2000;46:373–381
  45. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323–329
  46. Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys. 2003;55:110–115
  47. Claude L, Perol D, Ginestet C, et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol. 2004;71:175–181
  48. Lind PA, Wennberg B, Gagliardi G, et al. ROC curves and evaluation of radiation-induced pulmonary toxicity in breast cancer. Int J Radiat Oncol Biol Phys. 2006;64:765–770
  49. Kim TH, Cho KH, Pyo HR, et al. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology. 2005;235:208–215
  50. Lind PA, Marks LB, Hollis D, et al. Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. Int J Radiat Oncol Biol Phys. 2002;54:340–347
  51. Tsujino K, Hirota S, Kotani Y, et al. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation. Int J Radiat Oncol Biol Phys. 2006;64:1100–1105
  52. Hope AJ, Lindsay PE, El Naqa I, et al. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys. 2006;65:112–124
  53. Oetzel D, Schraube P, Hensley F, et al. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 1995;33:455–460
  54. Yorke ED, Jackson A, Rosenzweig KE, et al. Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:672–682
  55. Liao Z, Wang SL, Wei X, et al. Analysis of clinical and dosimetric factors associated with radiation pneumonitis (RP) in patients with non-small cell lung cancer (NSCLC) treated with concurrent chemotherapy (ConChT) and three dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2005;63:S41
  56. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:650–659
  57. Belderbos JS, De Jaeger K, Heemsbergen WD, et al. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol. 2003;66:119–126
  58. Tucker SL, Liao ZX, Travis EL. Estimation of the spatial distribution of target cells for radiation pneumonitis in mouse lung. Int J Radiat Oncol Biol Phys. 1997;38:1055–1066
  59. Yamada M, Kudoh S, Hirata K, et al. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer. 1998;34:71–75
  60. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006;65:640–645
  61. Gagliardi G, Lax I, Soderstrom S, et al. Prediction of excess risk of long-term cardiac mortality after radiotherapy of stage I breast cancer. Radiother Oncol. 1998;46:63–71
  62. Martel MK, Sahijdak WM, Ten Haken RK, et al. Fraction size and dose parameters related to the incidence of pericardial effusions. Int J Radiat Oncol Biol Phys. 1998;40:155–161
  63. Gagliardi G, Lax I, Ottolenghi A, et al. Long-term cardiac mortality after radiotherapy of breast cancer—Application of the relative seriality model. Br J Radiol. 1996;69:839–846
  64. Eriksson F, Gagliardi G, Liedberg A, et al. Long-term cardiac mortality following radiation therapy for Hodgkin’s disease: Analysis with the relative seriality model. Radiother Oncol. 2000;55:153–162
  65. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA. 1993;270:1949–1955
  66. Gyenes G, Rutqvist LE, Liedberg A, et al. Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer. Radiother Oncol. 1998;48:185–190
  67. Carr ZA, Land CE, Kleinerman RA, et al. Coronary heart disease after radiotherapy for peptic ulcer disease. Int J Radiat Oncol Biol Phys. 2005;61:842–850
  68. Hurkmans CW, Cho BC, Damen E, et al. Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. Radiother Oncol. 2002;62:163–171
  69. Gagliardi G, Lax I, Rutqvist LE. Partial irradiation of the heart. Semin Radiat Oncol. 2001;11:224–233
  70. Prosnitz RG, Chen YH, Marks LB. Cardiac toxicity following thoracic radiation. Semin Oncol. 2005;32:S71–S80
  71. Fein DA, Marcus RB, Parsons JT, et al. Lhermitte’s sign: incidence and treatment variables influencing risk after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 1993;27:1029–1033
  72. Alfonso ER, De Gregorio MA, Mateo P, et al. Radiation myelopathy in over-irradiated patients: MR imaging findings. Eur Radiol. 1997;7:400–404
  73. Rampling R, Symonds P. Radiation myelopathy. Curr Opin Neurol. 1998;11:627–632
  74. Schultheiss TE. Spinal cord radiation tolerance. Int J Radiat Oncol Biol Phys. 1994;30:735–736
  75. Schultheiss TE, Stephens LC, Jiang GL, et al. Radiation myelopathy in primates treated with conventional fractionation. Int J Radiat Oncol Biol Phys. 1990;19:935–940
  76. Macbeth FR, Wheldon TE, Girling DJ, et al. The Medical Research Council Lung Cancer Working Party Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. Clin Oncol (R Coll Radiol). 1996;8:176–181
  77. Jeremic B, Djuric L, Mijatovic L. Incidence of radiation myelitis of the cervical spinal cord at doses of 5500 cGy or greater. Cancer. 1991;68:2138–2141
  78. Philippens ME, Pop LA, Visser AG, et al. Dose-volume effects in rat thoracolumbar spinal cord: An evaluation of NTCP models. Int J Radiat Oncol Biol Phys. 2004;60:578–590
  79. Phillips TL, Buschke F. Radiation tolerance of the thoracic spinal cord. Am J Roentgenol Radium Ther Nucl Med. 1969;105:659–664
  80. Abbatucci JS, Delozier T, Quint R, et al. Radiation myelopathy of the cervical spinal cord: Time, dose and volume factors. Int J Radiat Oncol Biol Phys. 1978;4:239–248
  81. Kim YH, Fayos JV. Radiation tolerance of the cervical spinal cord. Radiology. 1981;139:473–478
  82. McCunniff AJ, Liang MJ. Radiation tolerance of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 1989;16:675–678
  83. Marcus RB, Million RR. The incidence of myelitis after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 1990;19:3–8
  84. Jeremic B, Shibamoto Y, Milicic B, et al. Absence of thoracic radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for stage III nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys. 1998;40:343–346
  85. van der Kogel AJ. Dose-volume effects in the spinal cord. Radiother Oncol. 1993;29:105–109
  86. Shirato H, Mizuta M, Miyasaka K. A mathematical model of the volume effect which postulates cell migration from unirradiated tissues. Radiother Oncol. 1995;35:227–231
  87. Marucci L, Niemierko A, Liebsch NJ, et al. Spinal cord tolerance to high-dose fractionated 3D conformal proton-photon irradiation as evaluated by equivalent uniform dose and dose volume histogram analysis. Int J Radiat Oncol Biol Phys. 2004;59:551–555
  88. Bloss JD, DiSaia PJ, Mannel RS, et al. Radiation myelitis: A complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix. Gynecol Oncol. 1991;43:305–308
  89. Gatcombe H, Lawson J, Phuphanich S, et al. Treatment related myelitis in hodgkin’s lymphoma following stem cell transplant, chemotherapy and radiation: a case report and review of the literature. J Neurooncol. 2006;79(3):293–298
  90. Raney B, Tefft M, Heyn R, et al. Ascending myelitis after intensive chemotherapy and radiation therapy in children with cranial parameningeal sarcoma. Cancer. 1992;69:1498–1506
  91. Nieder C, Grosu AL, Andratschke NH, et al. Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients. Int J Radiat Oncol Biol Phys. 2005;61:851–855
  92. Cheng JC, Chuang VP, Cheng SH, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2000;47:435–442
  93. Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005;15:279–283
  94. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method. Int J Radiat Oncol Biol Phys. 1989;16:1623–1630
  95. Lawrence TS, Ten Haken RK, Kessler ML, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys. 1992;23:781–788
  96. Xu ZY, Liang SX, Zhu J, et al. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys. 2006;65:189–195
  97. Dawson LA, Lawrence TS, Ten Haken RK. In response to Dr. Tome and Dr. Fenwick. Int J Radiat Oncol Biol Phys. 2004;58:1319–1320
  98. Liang SX, Zhu XD, Xu ZY, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys. 2006;65:426–434
  99. Cheng JC, Liu HS, Wu JK, et al. Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease. Int J Radiat Oncol Biol Phys. 2005;62:1150–1156
  100. Goldner G, Tomicek B, Becker G. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: Results of a prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys. 2007;67(1):78–83
  101. van Lin EN, Kristinsson J, Philippens ME, et al. Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy. Int J Radiat Oncol Biol Phys. 2006;Dec 7; [Epub ahead of print]
  102. Gilinsky NH, Burns DG, Barbezat GO, et al. The natural history of radiation-induced proctosigmoiditis: an analysis of 88 patients. Q J Med. 1983;52:40–53
  103. Dale E, Olsen DR, Fossa SD. Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43:385–391
  104. Rancati T, Fiorino C, Gagliardi G, et al. Fitting late rectal bleeding data using different NTCP models: Results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol. 2004;73:21–32
  105. Jackson A. Partial irradiation of the rectum. Semin Radiat Oncol. 2001;11:215–223
  106. Sandler HM, McLaughlin PW, Ten Haken RK, et al. Three dimensional conformal radiotherapy for the treatment of prostate cancer: Low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys. 1995;33:797–801
  107. Benk VA, Adams JA, Shipley WU, et al. Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma. Int J Radiat Oncol Biol Phys. 1993;26:551–557
  108. Boersma LJ, van den Brink M, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys. 1998;41:83–92
  109. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000;48:635–642
  110. Jackson A, Skwarchuk MW, Zelefsky MJ, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys. 2001;49:685–698
  111. Skwarchuk MW, Jackson A, Zelefsky MJ, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys. 2000;47:103–113
  112. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  113. Fellin G, Valdagni R, Rancati T, et al. Predictors of late rectal toxicity in high-dose 3D CRT for prostate cancer: Preliminary results from a prospective multicentric study performed by the AIRO National Working Group on Prostate Irradiation. 2006 Prostate Cancer Symposium. 2006;125:
  114. Akimoto T, Muramatsu H, Takahashi M, et al. Rectal bleeding after hypofractionated radiotherapy for prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding. Int J Radiat Oncol Biol Phys. 2004;60:1033–1039

PII: S1053-4296(06)00108-1

doi: 10.1016/j.semradonc.2006.11.007

Seminars in Radiation Oncology
Volume 17, Issue 2 , Pages 108-120 , April 2007

Article Tools

* Image Usage & Resolution